Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.84

Margin Of Safety %

-20

Put/Call OI Ratio

0.5

EPS Next Q Diff

-3.04

EPS Last/This Y

-0.96

EPS This/Next Y

13.02

Price

172.21

Target Price

221.07

Analyst Recom

1.29

Performance Q

-4.61

Upside

-223.4%

Beta

0.25

Ticker: JAZZ




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23JAZZ168.660.460.339843
2026-01-26JAZZ166.30.460.049853
2026-01-27JAZZ167.880.460.199865
2026-01-28JAZZ164.730.460.879908
2026-01-29JAZZ163.970.460.059906
2026-01-30JAZZ164.490.460.009916
2026-02-02JAZZ167.30.430.1310417
2026-02-03JAZZ166.820.430.1810415
2026-02-05JAZZ163.10.430.0010426
2026-02-09JAZZ1650.430.0810461
2026-02-10JAZZ165.660.420.5010472
2026-02-11JAZZ166.240.420.9610497
2026-02-12JAZZ166.20.467.8411516
2026-02-13JAZZ166.290.430.0011227
2026-02-17JAZZ167.30.420.5411249
2026-02-18JAZZ168.710.410.0911283
2026-02-19JAZZ169.510.404.3011517
2026-02-20JAZZ171.860.500.0212812
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23JAZZ168.78-3.01710.08.10
2026-01-26JAZZ166.32-3.01709.08.10
2026-01-27JAZZ167.84-3.01730.28.10
2026-01-28JAZZ165.40-3.01708.68.10
2026-01-29JAZZ163.94-2.81714.08.10
2026-01-30JAZZ164.52-2.81725.08.10
2026-02-02JAZZ167.31-2.71737.78.10
2026-02-03JAZZ166.80-1.51719.38.10
2026-02-04JAZZ165.72-1.51715.98.10
2026-02-05JAZZ163.15-1.51707.68.10
2026-02-06JAZZ165.45-1.51734.98.10
2026-02-09JAZZ164.96-1.51719.38.10
2026-02-10JAZZ165.72-1.21726.08.10
2026-02-11JAZZ166.23-1.21725.68.10
2026-02-12JAZZ166.17-1.21721.78.10
2026-02-13JAZZ166.26-1.21721.88.10
2026-02-17JAZZ167.93-1.41730.98.10
2026-02-18JAZZ168.76-1.41726.18.10
2026-02-19JAZZ169.54-1.4- 8.10
2026-02-20JAZZ172.21-1.4- 8.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23JAZZ-4.67-2.059.94
2026-01-26JAZZ-4.67-2.669.26
2026-01-27JAZZ-4.58-2.669.26
2026-01-28JAZZ-4.58-2.669.24
2026-01-29JAZZ-4.58-2.669.24
2026-01-30JAZZ-4.58-2.669.24
2026-02-02JAZZ-4.58-1.989.24
2026-02-03JAZZ-4.58-1.989.24
2026-02-04JAZZ-4.58-1.989.24
2026-02-05JAZZ-4.58-1.989.24
2026-02-06JAZZ-4.55-1.989.24
2026-02-09JAZZ-4.55-1.439.24
2026-02-10JAZZ-4.55-1.439.24
2026-02-11JAZZ-4.55-1.439.78
2026-02-12JAZZ-4.55-1.439.78
2026-02-13JAZZ-4.55-1.439.78
2026-02-17JAZZ-4.551.499.78
2026-02-18JAZZ-4.551.499.78
2026-02-19JAZZ-4.551.499.78
2026-02-20JAZZ-4.551.499.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

6.99

Avg. EPS Est. Current Quarter

6.41

Avg. EPS Est. Next Quarter

3.95

Insider Transactions

-4.55

Institutional Transactions

1.49

Beta

0.25

Average Sales Estimate Current Quarter

1155

Average Sales Estimate Next Quarter

996

Fair Value

137.71

Quality Score

48

Growth Score

63

Sentiment Score

96

Actual DrawDown %

8.9

Max Drawdown 5-Year %

-47.5

Target Price

221.07

P/E

Forward P/E

7.81

PEG

1.19

P/S

2.52

P/B

2.64

P/Free Cash Flow

7.83

EPS

-6.07

Average EPS Est. Cur. Y​

8.1

EPS Next Y. (Est.)

21.12

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-8.86

Relative Volume

1.31

Return on Equity vs Sector %

-38.3

Return on Equity vs Industry %

-20.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading

Float Short %

9.84

Margin Of Safety %

-20

Put/Call OI Ratio

0.5

EPS Next Q Diff

-3.04

EPS Last/This Y

-0.96

EPS This/Next Y

13.02

Price

172.21

Target Price

221.07

Analyst Recom

1.29

Performance Q

-4.61

Upside

-223.4%

Beta

0.25

Ticker: JAZZ




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23JAZZ168.660.460.339843
2026-01-26JAZZ166.30.460.049853
2026-01-27JAZZ167.880.460.199865
2026-01-28JAZZ164.730.460.879908
2026-01-29JAZZ163.970.460.059906
2026-01-30JAZZ164.490.460.009916
2026-02-02JAZZ167.30.430.1310417
2026-02-03JAZZ166.820.430.1810415
2026-02-05JAZZ163.10.430.0010426
2026-02-09JAZZ1650.430.0810461
2026-02-10JAZZ165.660.420.5010472
2026-02-11JAZZ166.240.420.9610497
2026-02-12JAZZ166.20.467.8411516
2026-02-13JAZZ166.290.430.0011227
2026-02-17JAZZ167.30.420.5411249
2026-02-18JAZZ168.710.410.0911283
2026-02-19JAZZ169.510.404.3011517
2026-02-20JAZZ171.860.500.0212812
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23JAZZ168.78-3.01710.08.10
2026-01-26JAZZ166.32-3.01709.08.10
2026-01-27JAZZ167.84-3.01730.28.10
2026-01-28JAZZ165.40-3.01708.68.10
2026-01-29JAZZ163.94-2.81714.08.10
2026-01-30JAZZ164.52-2.81725.08.10
2026-02-02JAZZ167.31-2.71737.78.10
2026-02-03JAZZ166.80-1.51719.38.10
2026-02-04JAZZ165.72-1.51715.98.10
2026-02-05JAZZ163.15-1.51707.68.10
2026-02-06JAZZ165.45-1.51734.98.10
2026-02-09JAZZ164.96-1.51719.38.10
2026-02-10JAZZ165.72-1.21726.08.10
2026-02-11JAZZ166.23-1.21725.68.10
2026-02-12JAZZ166.17-1.21721.78.10
2026-02-13JAZZ166.26-1.21721.88.10
2026-02-17JAZZ167.93-1.41730.98.10
2026-02-18JAZZ168.76-1.41726.18.10
2026-02-19JAZZ169.54-1.4- 8.10
2026-02-20JAZZ172.21-1.4- 8.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23JAZZ-4.67-2.059.94
2026-01-26JAZZ-4.67-2.669.26
2026-01-27JAZZ-4.58-2.669.26
2026-01-28JAZZ-4.58-2.669.24
2026-01-29JAZZ-4.58-2.669.24
2026-01-30JAZZ-4.58-2.669.24
2026-02-02JAZZ-4.58-1.989.24
2026-02-03JAZZ-4.58-1.989.24
2026-02-04JAZZ-4.58-1.989.24
2026-02-05JAZZ-4.58-1.989.24
2026-02-06JAZZ-4.55-1.989.24
2026-02-09JAZZ-4.55-1.439.24
2026-02-10JAZZ-4.55-1.439.24
2026-02-11JAZZ-4.55-1.439.78
2026-02-12JAZZ-4.55-1.439.78
2026-02-13JAZZ-4.55-1.439.78
2026-02-17JAZZ-4.551.499.78
2026-02-18JAZZ-4.551.499.78
2026-02-19JAZZ-4.551.499.78
2026-02-20JAZZ-4.551.499.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

6.99

Avg. EPS Est. Current Quarter

6.41

Avg. EPS Est. Next Quarter

3.95

Insider Transactions

-4.55

Institutional Transactions

1.49

Beta

0.25

Average Sales Estimate Current Quarter

1155

Average Sales Estimate Next Quarter

996

Fair Value

137.71

Quality Score

48

Growth Score

63

Sentiment Score

96

Actual DrawDown %

8.9

Max Drawdown 5-Year %

-47.5

Target Price

221.07

P/E

Forward P/E

7.81

PEG

1.19

P/S

2.52

P/B

2.64

P/Free Cash Flow

7.83

EPS

-6.07

Average EPS Est. Cur. Y​

8.1

EPS Next Y. (Est.)

21.12

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-8.86

Relative Volume

1.31

Return on Equity vs Sector %

-38.3

Return on Equity vs Industry %

-20.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading